The U.S. pharmaceutical supply chain faces a threat equal to the rare-earths challenge already posed by China’s exploitation of its dominance of those critical minerals. The authors provide a model th...

The U.S. pharmaceutical supply chain faces a threat equal to the rare-earths challenge already posed by China’s exploitation of its dominance of those critical minerals. The authors provide a model th...

Effects could be felt for months in the form on higher prices for generic drugs and spot shortages.

Podcast Episode · Medicine and Science from The BMJ · 20 March · 34min

Pharmaceutical company executives are responding to the immediate supply-chain threats by targeting unconventional routes

Drinks companies cut networks as rising costs and driver shortages undermine business model

To avoid tariffs, drug giants committed more than $480 billion to U.S.-based production. Two indicators gauge whether the pledges are real

A fifth of the world's generic drugs and over half of all vaccines are made in India, where children have died after taking toxic cough syrup. Here's what's being done about it. Plus: biodiversity los...

Tariffs won’t fix the country’s reliance on foreign medicines.

Tariffs won’t fix the country’s reliance on foreign medicines.

Tariffs won’t fix the country’s reliance on foreign medicines.

Cascading adoption of most-favored-nation drug pricing could erode affordable access to essential medicines

Cascading adoption of most-favored-nation drug pricing could erode affordable access to essential medicines

The World Health Organization plans to officially back the use of weight-loss drugs to treat obesity in adults for the first time, a memo reviewed by Reuters on Thursday shows, marking a shift in its approach to treating the global health problem.

Heparin is cheap and essential to millions of hospitalized people. Tariffs could disrupt the supply chain that gets ingredients from China to their beds.

The loss of U.S. funding could leave Gavi with three options to downsize its operations

Global health agencies can teach valuable lessons about drug supply risks and upstream supply chains

An analysis of the short- and long-term challenges and benefits